Development of abiraterone for the treatment of prostate cancer
- Submitting institution
-
Institute of Cancer Research: Royal Cancer Hospital (The)
- Unit of assessment
- 1 - Clinical Medicine
- Summary impact type
- Health
- Request cross-referral to
- -
- Is this case study continued from a case study submitted in 2014?
- Yes
- Underpinning research subjects
-
- Clinical Sciences
- Oncology And Carcinogenesis
- Public Health And Health Services
3. References to the research
5. Sources to corroborate the impact
Additional contextual information
Grant funding
| Grant number |
Value of grant |
| BCT013X (internal) |
£242,263 |
| A7401 |
£3,767,251 |
| None given (ECMC 2007) |
£1,250,000 |
| SP2330/0202 |
£5,316,438 |
| C12540/A15573 |
£750,000 |
| None given (ECMC 2012) |
£750,000 |
| PCC004X (internal) |
£248,208 |
| PCF003X (internal) |
£142,939 |
| PRC010X (internal) |
£248,028 |
| 3002498347 |
£6,311,883 |
| G0501019 |
£1,941,064 |
| A12459 |
£0 |
| 651 CL-2008-22-001 |
£7,004 |
| C51/A7401 |
£1,327,284 |
| BRC-2011-10059 |
£61,543,735 |
| MC_UU_12023/25 |
£0 |
| G0601308 |
£794,215 |
- Countries
-
- US
- Austria
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czechia
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Poland
- Portugal
- Romania
- Slovakia
- Slovenia
- Spain
- Sweden
- Iceland
- Liechtenstein
- Norway
- UK
- Argentina
- Australia
- Brazil
- Canada
- Chile
- China
- Colombia
- Israel
- Japan
- South Korea
- Malaysia
- Mexico
- New Zealand
- Russia
- South Africa
- Turkey
- Ukraine
- Formal partners
-
- Boehringer Ingelheim
- The Royal Marsden NHS Foundation Trust
- Cougar Biotech
- British Technology Group
- Johnson & Johnson
- Funding programmes
-
- Bob Champion Cancer Trust: Management of Early Human Prostate Cancer
- Cancer Research UK: Experimental Cancer Medicine Centre (2007)
- Department of Health: Experimental Cancer Medicine Centre (2007)
- Cancer Research UK: Cancer Therapeutics Unit Core funding (1998)
- Cancer Research UK: Experimental Cancer Medicine Centre (2012)
- Department of Health: Experimental Cancer Medicine Centre (2012)
- Prostate Cancer UK: CYP17 Inhibition with Abiraterone
- Prostate Cancer Research Foundation: Laboratory evaluation of Abiraterone
- Prostate Research Campaign UK: CYP17 Inhibition with Abiraterone
- Stand Up To Cancer: Precision Therapy of Advanced Prostate Cancer
- Medical Research Council: NCRI Prostate Cancer Collaborative
- Cancer Research UK: STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy - An Extension to Assess Abiraterone
- National Institute of Health Research: Academic Clinical Lecturer (ACL)
- Department of Health: Section of Medicine funding
- The National Institute for Health Research Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (2012)
- Medical Research Council: STAMPEDE Trial funding
- Medical Research Council: Circulating Tumour Cell Enumeration and Molecular Evaluation in Patients with Advanced Prostate Carcinoma.
- Global research identifiers
-
- n/a
- grid.11485.39
- grid.57981.32
- grid.453276.1
- grid.453146.1
- n/a
- grid.430427.6
- grid.420006.0
- grid.451056.3
- Name of funders
-
- Bob Champion Cancer Trust
- Cancer Research UK
- Department of Health
- Prostate Cancer UK
- Prostate Cancer Research Foundation
- Prostate Research Campaign UK
- Stand Up To Cancer (part of the Entertainment Industry Foundation)
- Medical Research Council
- National Institute of Health Research
- Researcher ORCIDs
-
- 0000-0002-4766-5304
- 0000-0002-2034-595X
- 0000-0002-3954-2806
- 0000-0003-4122-744X
- 0000-0002-4811-7983
